Cristina Puy
Overview
Explore the profile of Cristina Puy including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
650
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yang C, Shorey-Kendrick L, Puy C, Benson A, Wilmarth P, Reddy A, et al.
Res Pract Thromb Haemost
. 2025 Mar;
9(1):102676.
PMID: 40070370
Background: Amniotic fluid (AF) plays a key role in fetal development, yet the evolving composition of AF and its effects on hemostasis and thrombosis are poorly understood. Objectives: To characterize...
2.
New mechanisms and therapeutic approaches to regulate vascular permeability in systemic inflammation
Vu H, Moellmer S, McCarty O, Puy C
Curr Opin Hematol
. 2025 Mar;
PMID: 40063579
Purpose Of Review: This review summarizes mechanisms that regulate endothelial vascular permeability in health and disease. In systemic inflammation, the endothelial barrier integrity is disrupted, which exacerbates vascular permeability, leading...
3.
Lira A, Liu T, Aslan J, Puy C, McCarty O
Biochim Biophys Acta Biomembr
. 2025 Feb;
1867(3):184415.
PMID: 39922445
Lipopolysaccharides (LPS) are key bacterial membrane components that activate coagulation factor XII (FXII), establishing a critical link between bacterial infections, blood coagulation, and inflammation. This study investigates how the supramolecular...
4.
Lira A, Taskin B, Puy C, Keshari R, Silasi R, Pang J, et al.
J Biol Chem
. 2024 Dec;
301(1):108110.
PMID: 39706265
Lipopolysaccharide (LPS) is the primary pathogenic factor in Gram-negative sepsis. While the presence of LPS in the bloodstream during infection is associated with disseminated intravascular coagulation, the mechanistic link between...
5.
Puy C, Moellmer S, Pang J, Vu H, Melrose A, Lorentz C, et al.
Blood
. 2024 Aug;
144(17):1821-1833.
PMID: 39158072
Loss of endothelial barrier function contributes to the pathophysiology of many inflammatory diseases. Coagulation factor XI (FXI) plays a regulatory role in inflammation. Although activation of FXI increases vascular permeability...
6.
Keeling N, Wallisch M, Johnson J, Le H, Vu H, Jordan K, et al.
J Thromb Haemost
. 2024 Feb;
22(5):1433-1446.
PMID: 38331196
Background: Cardiovascular implantable devices, such as vascular stents, are critical for the treatment of cardiovascular diseases. However, their success is dependent on robust and often long-term antithrombotic therapies. Yet, the...
7.
Kohs T, Vu H, Jordan K, Parra-Izquierdo I, Hinds M, Shatzel J, et al.
Res Pract Thromb Haemost
. 2024 Jan;
8(1):102276.
PMID: 38226339
Background: Hyperlipidemia is associated with chronic inflammation and thromboinflammation. This is an underlying cause of several cardiovascular diseases, including atherosclerosis. In diseased blood vessels, rampant thrombin generation results in the...
8.
Pfeffer M, Kohs T, Vu H, Jordan K, Wang J, Lorentz C, et al.
Arterioscler Thromb Vasc Biol
. 2023 Nov;
44(1):290-299.
PMID: 37970718
Background: Despite the ubiquitous utilization of central venous catheters in clinical practice, their use commonly provokes thromboembolism. No prophylactic strategy has shown sufficient efficacy to justify routine use. Coagulation factors...
9.
Moellmer S, Puy C, McCarty O
Blood
. 2023 Oct;
143(15):1445-1454.
PMID: 37874916
Unique among coagulation factors, the coagulation factor XI (FXI) arose through a duplication of the gene KLKB1, which encodes plasma prekallikrein. This evolutionary origin sets FXI apart structurally because it...
10.
Taskin B, Kohs T, Shatzel J, Puy C, McCarty O
Curr Opin Hematol
. 2023 Sep;
31(1):32-38.
PMID: 37694771
Purpose Of Review: This review summarizes the pathophysiology and potential therapeutic options for treatment of multiple sclerosis, a common neuronal demyelinating disorder affecting 2.2 million people worldwide. As an autoimmune...